Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1906 Download: 162 Web of Science: 1 Crossref: 1

Prospect of emerging treatments for hepatitis B virus functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(Suppl):S165-181. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0855

View: 2276 Download: 364 Web of Science: 2 Crossref: 5

Original Article

Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters

Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(2):460-473. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0724

View: 1187 Download: 104

Editorial

MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”

Rex Wan-Hin Hui, Lung-Yi Mak

Clin Mol Hepatol. 2025;31(1):290-292. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0630

View: 1035 Download: 31 Crossref: 2

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 3040 Download: 98 Web of Science: 3 Crossref: 4

Review

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 6815 Download: 276 Web of Science: 23 Crossref: 21

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 7023 Download: 355 Web of Science: 21 Crossref: 20

Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective

Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):217-229. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0399

View: 7605 Download: 263 Web of Science: 15 Crossref: 16

Correspondence

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”

Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):191-193. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0410

View: 3681 Download: 75

Original Article

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 7186 Download: 247 Web of Science: 21 Crossref: 17

Review

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 11090 Download: 692 Web of Science: 56 Crossref: 59

1 |

Viewed By 10565	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7446	MAFLD: How is it different from NAFLD?
Viewed By 5390	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4819	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4809	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search